Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.57 |
| ▸ | PAM | P19021 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272534 | 0.87 | TRPV1 (0.78) | ALDH1A1TRPV1 | |
| SCHEMBL30629784 | 0.87 | TRPV1 (0.78) | ALDH1A1TRPV1 | |
| SCHEMBL14763569 | 0.87 | TRPV1 (0.78) | ALDH1A1TRPV1 | |
| SCHEMBL272535 | 0.87 | TRPV1 (0.78) | ALDH1A1TRPV1 | |
| SCHEMBL9240814 | 0.85 | TRPV1 (0.76) | ALDH1A1TRPV1 | |
| SCHEMBL28249370 | 0.82 | TRPV1 (0.71) | ALDH1A1TRPV1 | |
| SCHEMBL21598324 | 0.82 | TRPV1 (0.71) | ALDH1A1MAPK1L3MBTL1TRPV1 | |
| SCHEMBL19183137 | 0.80 | ALDH1A1 (0.63) | ALDH1A1MAPK1L3MBTL1PAMTSHR | |
| SCHEMBL203679 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MAPK1L3MBTL1PAMTSHR | |
| Hydrochloric Acid SCHEMBL25259767 | 0.77 | ALDH1A1 (0.59) | ALDH1A1MAPK1L3MBTL1PAMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2341042-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| EP-2626350-B1 | CYCLOPROPANE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2015-04-15 | — | — | EP | disclosed |
| US-8680328-B2 | Method for producing optically active cyclopropane carboxylic acid ester compound, asymmetric copper complex, and optically active salicylideneaminoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-03-25 | — | — | US | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-07-07 | — | — | US | disclosed |
| EP-2341042-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2011-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166372-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE CARBOXYLIC ACID ESTER COMPOUND, ASYMMETRIC COPPER COMPLEX, AND OPTICALLY ACTIVE SALICYLIDENEAMINOALCOHOL COMPOUND | ALDH18A1, ALDH3A1, DECR1 | ALDH1A1 30/4885MAPK1 2654/4885L3MBTL1 2495/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | ALDH1A1 2708/4885MAPK1 1433/4885L3MBTL1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.